- ​​​​​Compass Pathways plc (NASDAQ:CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression.
- The study has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks, with rapid and durable treatment response.
- The 10mg vs. 1mg dose did not show a statistically significant difference at week 3.
- At least twice the number of patients in the 25mg group showed a response and remission at week 3 and week 12, compared with the 1mg group.
- COMP360 was generally well tolerated, with more than 90% of treatment-emergent adverse events being mild or moderate in severity.
- The Company plans to start a pivotal phase 3 program in 2022.
- Compass posted a Q3 EPS loss of $(0.38) higher than $(1.30) a year ago.
- Cash and cash equivalents were $294.0 million.
- Price Action: CMPS shares up 7.78% at $39.71 during the premarket session on the last check Tuesday.
Ondas Holdings Q2 EPS $(0.10) Beats $(0.12) Estimate, Sales $887.00K Miss $1.22M Estimate
Ondas Holdings (NASDAQ:ONDS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. The company reported quarterly sales of $887.00 thousand which missed
